Pharmacokinetic Evaluation of POSaconazole boosted Fosamprenavir (EPOS)

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 24

Inclusion Criteria

-Subject is at least 18 and not older than 55 years of age on the day of the first dosing.
- Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to the first dosing.
- Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes in-cluded.
- Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.
- Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to the first dose. Results of biochemistry, hae-matology and urinalysis testing should be within the laboratory's reference ranges (see Appendix A) If laboratory results are not within the reference ranges, the subject is included on condition that the Investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
- Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement.

Exclusion Criteria

- Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- Positive HIV test.
- Positive hepatitis B or C test.
- Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the first dose) or breast-feeding female.
-Therapy with any drug (for two weeks preceding dosing), except for paracetamol.
- Subjects with an ECG with QTc interval greater than 450 msec for men, and greater than 470 msec for women at screening.
-Relevant history or presence of pulmonary disorders (especially COPD), cardiovascu-lar disorders, neurological disorders (especially seizures and migraine), gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabe-tes mellitus), coagulation disorders.
-Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- History of or current abuse of drugs, alcohol or solvents.
- Inability to understand the nature and extent of the trial and the procedures required.
11. Participation in a drug trial within 60 days prior to the first dose.
12. Donation of blood within 60 days prior to the first dose.
13. Febrile illness within 3 days before the first dose

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-To determine the effect of posaconazole on fosamprenavir pharmacokinetics<br /><br>(AUC, Cmax, Cmin)<br /><br>-To determine the effect of fosamprenavir on posaconazole pharmacokinetics<br /><br>(AUC, Cmax, Cmin)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-Adverse effects which are either due to posaconazole, fosamprenavir/ ritonavir<br /><br>or combined use of posaconazole and<br /><br>fosamprenavir.</p><br>